COVID-19 Therapeutics – Product Information
This page contains product-specific information and resources for Texas COVID-19 therapeutics providers. Providers with questions can contact therapeutics@dshs.texas.gov or call Provider Support at 833-832-7068, option 0.
Bebtelovimab (Lilly)
- Emergency Use Authorization (EUA) for emergency use of bebtelovimab
- Bebtelovimab Fact Sheet for U.S. Health Care Providers (English)
- FDA Frequently Asked Questions on the Emergency Use Authorization of Bebtelovimab
- Bebtelovimab Fact Sheet for Patients and Caregivers (English)
- Bebtelovimab Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
- Bebtelovimab shelf-life extended (ASPR)
Bamlanivimab and Etesevimab (Lilly)
- Shelf-Life Extension for Bamlanivimab (ASPR)
- Shelf-Life Extension of Bamlanivimab and Etesevimab
- Emergency Use Authorization (EUA) for emergency use of bamlanivimab and etesevimab
- Bamlanivimab and Etesevimab Fact Sheet for Healthcare Providers
- FDA Frequently Asked Questions on the Emergency Use Authorization for Bamlanivimab and Etesevimab
- Dear HCP Letter: Bamlanivimab and Etesevimab, Preventing Medication Errors
- Bamlanivimab and Etesevimab Fact Sheet for Patients, Parents and Caregivers (English)
- Bamlanivimab and Etesevimab Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores: Autorización de uso de emergencia (EUA) de bamlanivimab y etesevimab para la enfermedad por coronavirus 2019 (COVID-19)
- Lilly bamlanivimab and etesevimab information
- Lilly Bamlanivimab and Etesevimab Together Antibody Playbook
Note: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab when given alone
Casirivimab/Imdevimab (Regeneron)
- Shelf-Life Extension for REGEN-COV (ASPR)
- Emergency Use Authorization (EUA) for emergency use of casirivimab and imdevimab
- FDA Frequently Asked Questions on the Emergency Use Authorization of Casirivimab + Imdevimab
- Casirivimab/Imdevimab Fact Sheet for U.S. Health Care Providers (English)
- REGEN-COV: Subcutaneous Injection Instructions for Healthcare Providers
- Important Prescribing Information: A Letter from Regeneron to Healthcare Providers on Preventing Medication Errors
- REGEN-COV Packaging Overview
- REGEN-COV (casirivimab and imdevimab) Fact Sheet for Patients and Caregivers (English)
- REGEN-COV (casirivimab and imdevimab) Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
- Regeneron casirivimab/imdevimab information
- Regeneron casirivimab/imdevimab guidebook
- Overview, Allocation & Distribution (casirivimab/imdevimab)
Sotrovimab (GlaxoSmithKline)
- Shelf-Life Extension for Sotrovimab (ASPR)
- Sotrovimab Fact Sheet for U.S. Health Care Providers (English)
- Emergency Use Authorization (EUA) for emergency use of sotrovimab
- FDA Frequently Asked Questions on the Emergency Use Authorization of Sotrovimab
- Sotrovimab Fact Sheet for Patients and Caregivers (English)
- Sotrovimab Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
- GlaxoSmithKline sotrovimab information
- A Detailed Guide for the Use of Sotrovimab
- Access & Reimbursement Information for Sotrovimab
Evusheld (tixagevimab co-packaged with cilgavimab) (AstraZeneca)
- Shelf-Life Extension for Evusheld (ASPR)
- Emergency Use Authorization (EUA) for emergency use of Evusheld
- Evusheld Fact Sheet for Healthcare Providers
- NIH Statement on Evusheld for Pre-Exposure Prophylaxis
- Frequently Asked Questions on the Emergency Use Authorization for Evusheld
- Evusheld Fact Sheet for Patients, Parents, and Caregivers (English)
- Evusheld Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
- AstraZeneca Evusheld information
- AstraZeneca Evusheld Coding Resource
- US HHS ASPR Frequently Asked Questions
Lagevrio (molnupiravir) (Merck)
- Emergency Use Authorization (EUA) for emergency use of Lagevrio
- Lagevrio Fact Sheet for Healthcare Providers (English)
- Hoja de Datos para Proveedores de atención médica para Lagevrio
- Frequently Asked Questions on the Emergency Use Authorization for Lagevrio
- Healthcare Provider Letter: Important Safety Information Regarding Use of Lagevrio in Pregnancy and Individuals of Childbearing Potential
- Prescriber Checklist for Lagevrio
- Lagevrio Fact Sheet for Patients, Parents, and Caregivers (English)
- Lagevrio Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
- US HHS ASPR Frequently Asked Questions
Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) (Pfizer)
- Emergency Use Authorization (EUA) for emergency use of Paxlovid
- Paxlovid Fact Sheet for Healthcare Providers (English)
- PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers (FDA)
- Frequently Asked Questions on the Emergency Use Authorization for Paxlovid
- NIH Statement on Paxlovid Drug-Drug Interactions
- Healthcare Provider Letter: PAXLOVID EUA dosing and dispensing in moderate renal impairment, and risk of serious adverse reactions due to drug interactions
- COVID-19 Drug Interactions Checker (University of Liverpool) – (app available)
- Paxlovid Drug Interaction Checker
- Management of Drug Interactions With Paxlovid: Resource for Clinicians (The Infectious Diseases Society of America)
- Instructions for Pharmacists for Paxlovid (Pfizer)
- Important Dispensing Information for Patients with Moderate Renal Impairment
- Paxlovid Fact Sheet for Patients, Parents, and Caregivers (English)
- Paxlovid Fact Sheet for Patients, Parents and Caregivers (Spanish) | Hoja informativa para pacientes, padres y cuidadores
- Q&A with FDA Director of the Office of Infectious Diseases about Paxlovid Updates (FDA)
- Shelf life extension for Paxlovid
- US HHS ASPR Frequently Asked Questions
This page is being updated as new information becomes available.